FIELD: medicine.
SUBSTANCE: group of inventions relates to treatment or prophylaxis of disorders of the meibomian glands. It includes two objects: 1) an agent for the treatment or prophylaxis of disorders diffuse meibomian gland seal or meibomian glands, clarithromycin, which contains as an active ingredient, and 2) the appropriate use of clarithromycin. Technical result is to reduce the telangiectasia and to reduce the number of mouths clogged meibomian glands.
EFFECT: dosage form is preferably an eye drop or an ophthalmic ointment.
8 cl, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENT FOR MEIBOMIAN GLAND DYSFUNCTION | 2014 |
|
RU2709542C2 |
| METHOD FOR CARRYING OUT COMBINED TREATMENT OF MEIBOMIAN GLANDS DYSFUNCTION CASES | 2006 |
|
RU2314102C1 |
| METHOD FOR ASSESSING MORPHOFUNCTIONAL STATUS OF MEIBOMIAN GLANDS - MEIBOMIAN GLANDS BIOMETRY | 2014 |
|
RU2567829C1 |
| COMPOSITIONS AND METHODS OF TREATING MEIBOMIAN DYSFUNCTION | 2015 |
|
RU2730464C2 |
| COMPOSITIONS BASED ON SELENIUM DISULFIDE FOR USE IN TREATMENT OF DYSFUNCTION OF MEIBOMIAN GLANDS | 2017 |
|
RU2778231C1 |
| METHODS AND COMPOSITIONS FOR TREATING DRY EYE DISEASE AND OTHER EYE DISEASES | 2016 |
|
RU2691412C2 |
| METHOD FOR COMPLEX THERAPY OF DYSFUNCTION OF THE MEIBOMIAN GLANDS | 2022 |
|
RU2790805C1 |
| COMPOSITION, METHOD FOR TRANSDERMAL DELIVERY OF POLYAFRON, METHOD FOR CONTROLLED RELEASE OF INGREDIENT | 2016 |
|
RU2758335C2 |
| METHOD OF DETERMINING DEGREE OF BLEPHAROCONJUNCTIVAL FORM OF DRY EYE SYNDROME | 2012 |
|
RU2500340C1 |
| METHOD OF DETERMINING FUNCTIONAL STATE OF TARSAL GLANDS | 2008 |
|
RU2373832C1 |
